TCR sequencing of B8-FL8–specific CD8+ T cells
Patient ID (IMGT nomenclature for TCRβ-variable regions) . | Vβ region . | Dβ region . | Jβ region . | . | Clonotypes, no./no. total . | Vβ staining, % . |
|---|---|---|---|---|---|---|
| AC-42 | ||||||
| BV2S1 (20-1) | C S A | Q G V A G G P | Y E Q Y | 2.7 | 1/82 | 3.42 |
| BV2S1 (20-1) | C S A | R D D L G R V G | N Q P Q H | 1.5 | 1/82 | 3.42 |
| BV4S1 (29-1) | C S V | E D R G T G V V | N E Q F | 2.1 | 2/82 | NA |
| BV6S5 (7-2) | C A S S | L E R D | Y E Q Y | 2.7 | 1/82 | NA |
| BV8S1 (12-3) | C A S S | F F S G T A S | Q P Q H | 1.5 | 77/82 | 74.36 |
| AC-14 | ||||||
| BV7S1 (4-1) | C A S S | Q E Q G R V V G | N E Q F | 2.1 | 4/54 | 13.31 |
| BV5S5 (5-4) | C A S S | L A A L D R V G W | D T Q Y | 2.3 | 2/54 | NA |
| BV5S2 (5-6) | C A S S | L A A L D R V G W | D T Q Y | 2.3 | 3/54 | 1.92 |
| BV5S5 (5-4) | C A S | I L A R G G V W T | D T Q Y | 2.3 | 36/54 | NA |
| BV5S1 (5-1) | C A S S | F T G A T D | Y D Y T | 1.2 | 8/54 | 10.66 |
| BV3S1 (28) | C A | T Q T D R P V S D | Q P Q H | 1.5 | 1/54 | 2.53 |
| AC-15 | ||||||
| BV12S1 (10-3) | C A I S | E T G E | E T Q Y | 2.5 | 2/21 | 9.35 |
| BV14S1 (27) | C A S S | L G Q G L A | N Y G Y T | 1.2 | 3/21 | 13.73 |
| BV20S1 (30) | C A W | D V K D R R I G | N E Q F | 2.1 | 5/21 | 10.18 |
| BV22S1 (2) | C A S S | E F P G L | S Y E Q Y | 2.7 | 1/21 | 12.38 |
| BV2S1 (20-1) | C S A R | A Q R T | Y G Y T | 1.2 | 1/21 | 35.23 |
| BV2S1 (20-1) | C S A | T I L A G V P Y G | E Q Y | 2.7 | 6/21 | 35.23 |
| BV2S1 (20-1) | C S A | S S Q R G G I | Y E Q Y | 2.7 | 3/21 | 35.23 |
Patient ID (IMGT nomenclature for TCRβ-variable regions) . | Vβ region . | Dβ region . | Jβ region . | . | Clonotypes, no./no. total . | Vβ staining, % . |
|---|---|---|---|---|---|---|
| AC-42 | ||||||
| BV2S1 (20-1) | C S A | Q G V A G G P | Y E Q Y | 2.7 | 1/82 | 3.42 |
| BV2S1 (20-1) | C S A | R D D L G R V G | N Q P Q H | 1.5 | 1/82 | 3.42 |
| BV4S1 (29-1) | C S V | E D R G T G V V | N E Q F | 2.1 | 2/82 | NA |
| BV6S5 (7-2) | C A S S | L E R D | Y E Q Y | 2.7 | 1/82 | NA |
| BV8S1 (12-3) | C A S S | F F S G T A S | Q P Q H | 1.5 | 77/82 | 74.36 |
| AC-14 | ||||||
| BV7S1 (4-1) | C A S S | Q E Q G R V V G | N E Q F | 2.1 | 4/54 | 13.31 |
| BV5S5 (5-4) | C A S S | L A A L D R V G W | D T Q Y | 2.3 | 2/54 | NA |
| BV5S2 (5-6) | C A S S | L A A L D R V G W | D T Q Y | 2.3 | 3/54 | 1.92 |
| BV5S5 (5-4) | C A S | I L A R G G V W T | D T Q Y | 2.3 | 36/54 | NA |
| BV5S1 (5-1) | C A S S | F T G A T D | Y D Y T | 1.2 | 8/54 | 10.66 |
| BV3S1 (28) | C A | T Q T D R P V S D | Q P Q H | 1.5 | 1/54 | 2.53 |
| AC-15 | ||||||
| BV12S1 (10-3) | C A I S | E T G E | E T Q Y | 2.5 | 2/21 | 9.35 |
| BV14S1 (27) | C A S S | L G Q G L A | N Y G Y T | 1.2 | 3/21 | 13.73 |
| BV20S1 (30) | C A W | D V K D R R I G | N E Q F | 2.1 | 5/21 | 10.18 |
| BV22S1 (2) | C A S S | E F P G L | S Y E Q Y | 2.7 | 1/21 | 12.38 |
| BV2S1 (20-1) | C S A R | A Q R T | Y G Y T | 1.2 | 1/21 | 35.23 |
| BV2S1 (20-1) | C S A | T I L A G V P Y G | E Q Y | 2.7 | 6/21 | 35.23 |
| BV2S1 (20-1) | C S A | S S Q R G G I | Y E Q Y | 2.7 | 3/21 | 35.23 |
TCR nucleotide sequences and predicted amino acid sequences of the purified T-cell populations. The number of sequences and the total number of molecular clones with rearranged TCR sequences are indicated as well as the frequency of Vβ regions determined at a separate study visit. Data for AC-42 clonotypes are presented for day 1026, and those for Vβ staining are from day 1110. Data for AC-14 clonotypes are from day 1440, and those for Vβ staining are from day 1500. Data for AC-15 clonotypes are from day 1437, and those for Vβ staining are from day 1332.
NA indicates that no commercial antibody was available against this Vβ region.